Pfizer Inc (PFE) 35.14 $PFE
Pfizer is expanding its vaccine portfolio, developing others
By The Associated Press - AP - Tue Jul 21, 5:08PM CDT
Pfizer has expanded its research on vaccines to eventually safeguard people from cradle to grave, from shots for pregnant women to protect their babies from the moment of birth to vaccines for senior citizens with waning immune systems, company officials said Tuesday during a media briefing.
BAX: 37.85 (+0.19), PFE: 35.14 (-0.10)
Business Highlights
By The Associated Press - AP - Tue Jul 21, 5:00PM CDT
___
JPM: 69.10 (-0.16), PFE: 35.14 (-0.10), C: 59.10 (+0.25), AMGN: 163.70 (-0.64), BAC: 18.08 (-0.04)
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 1:52PM CDT
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
AGN: 317.00 (-0.75), JNJ: 100.34 (-0.03), ACHN: 9.26 (-0.10), PFE: 35.14 (-0.10), ABBV: 70.54 (-0.26), JUNO: 50.10 (-0.03), LLY: 85.57 (-2.30), SNY: 52.99 (-0.26)
Pharma Stock Outlook - July 2015 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 1:52PM CDT
Pharma Stock Outlook - July 2015 - Industry Outlook
AGN: 317.00 (-0.75), JNJ: 100.34 (-0.03), ACHN: 9.26 (-0.10), PFE: 35.14 (-0.10), ABBV: 70.54 (-0.26), JUNO: 50.10 (-0.03), LLY: 85.57 (-2.30), SNY: 52.99 (-0.26)
Europe approves Amgen's first-in-class cholesterol drug
By MATTHEW PERRONE - AP - Tue Jul 21, 1:32PM CDT
WASHINGTON (AP) — Amgen on Tuesday received European approval for its first-of-a-kind cholesterol drug that lowers levels of the artery-clogging substance more than older drugs that have been prescribed for decades.
PFE: 35.14 (-0.10), AMGN: 163.70 (-0.64)
Global Fibrosis Therapeutics Pipeline Report 2015 - 32 Companies & 51 Drug Profiles
M2 - Tue Jul 21, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjw3lt/fibrosis) has announced the addition of the "Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - AiCuris GmbH & Co. KG - AnaMar AB - Arena Pharmaceuticals, Inc. - Bristol-Myers Squibb Company - Digna Biotech, S.L. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Five Prime Therapeutics, Inc. - Galectin Therapeutics, Inc. - GenKyoTex S.A. - GlycoMimetics, Inc. - HanAll Biopharma Co., Ltd. - Intercept Pharmaceuticals, Inc. - Isarna Therapeutics GmbH - KineMed, Inc. - Lycera Corp. - MandalMed, Inc. - miRagen Therapeutics, Inc. - Neumedicines Inc. - Pfizer Inc. - Promedior, Inc. - ProMetic Life Sciences Inc. - RuiYi Inc. - Scholar Rock, Inc. - Siena Biotech S.p.A. - SK Chemicals Co., Ltd. - Taisho Pharmaceutical Co., Ltd. - TRACON Pharmaceuticals, Inc. - UCB S.A. - Vericel Corporation - VivaCell Biotechnology Espana S.L. For more information visit http://www.researchandmarkets.com/research/rjw3lt/fibrosis
VCEL: 3.47 (-0.08), KNMD: (), PFE: 35.14 (-0.10), GALT: 2.67 (+0.03), GLYC: 7.52 (+0.10), BMY: 68.87 (-1.10), ICPT: 271.32 (-5.83), FGEN: 24.67 (-0.07), TCON: 13.13 (unch), ARNA: 4.30 (-0.05), XLRN: 30.79 (-1.79), FPRX: 24.89 (-0.29)
Sickle Cell Disease Pipeline Review, H1 2015 - 27 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rrc4sf/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Alnylam Pharmaceuticals, Inc. - Bluebird bio, Inc. - Bristol-Myers Squibb Company - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Erytech Pharma SA - Gamida Cell Ltd. - Gilead Sciences, Inc. - Global Blood Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Johnson & Johnson - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - Pfizer Inc. - PharmaEssentia Corporation - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sangamo BioSciences, Inc. - Sanofi - SynZyme Technologies, LLC For more information visit http://www.researchandmarkets.com/research/rr...ickle_cell
JNJ: 100.34 (-0.03), ISIS: 56.18 (+0.50), GILD: 117.78 (-0.42), PFE: 35.14 (-0.10), SGMO: 9.71 (-0.25), BMY: 68.87 (-1.10), NVS: 103.71 (-2.41), XLRN: 30.79 (-1.79)
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Pipeline Report 2015 - 37 Companies & 57 Drug Profiles
M2 - Tue Jul 21, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vgmkjs/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Absynth Biologics Limited - Actelion Ltd - ActogeniX NV - Adenium Biotech ApS - AIMM Therapeutics B.V. - Akthelia pharmaceuticals ehf - AmpliPhi Biosciences Corporation - Assembly Biosciences, Inc. - AvidBiotics Corp. - C3 Jian, Inc - Daiichi Sankyo Company, Limited - Evec, Inc. - GangaGen Inc. - ImmunoBiology Ltd. - Immuron Limited - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Merck & Co., Inc. - MGB Biopharma Limited - Microbiotix, Inc. - Micropharm Ltd - Nanotherapeutics, Inc. - Novabiotics Ltd - Oragenics, Inc. - Pfizer Inc. - Procarta Biosystems Ltd - Prokarium Ltd. - Sanofi Pasteur SA - Sarum Biosciences Limited - Sequella, Inc. - Shire Plc - Sorrento Therapeutics, Inc. - Stellar Biotechnologies, Inc. - Summit Therapeutics plc. - Synthetic Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/vg...lostridium
PFE: 35.14 (-0.10), SRNE: 23.98 (-0.01), INO: 7.31 (-0.19), SYN: 3.41 (+0.24), MRK: 58.67 (-0.33), SHPG: 255.23 (-2.57), ASMB: 16.99 (-0.46), OGEN: 1.74 (+0.04)
Low Back Pain Therapeutics Pipeline Review 2015 - 17 Companies & 19 Drug Profiles
M2 - Tue Jul 21, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qrggl2/low_back_pain) has announced the addition of the "Low Back Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aestus Therapeutics, Inc. - Astellas Pharma Inc. - Collegium Pharmaceutical, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Frontier Biotechnologies Co., Ltd - Grunenthal GmbH - Ipsen S.A. - MEDRx Co., Ltd. - Merck & Co., Inc. - Mesoblast Limited - Nektar Therapeutics - Pacira Pharmaceuticals, Inc. - Paladin Labs Inc. - Pfizer Inc. - Stayble Therapeutics - Teikoku Pharma USA, Inc. Drug Profiles - (acetaminophen tramadol hydrochloride) - (diclofenac sodium eperisone) - (etodolac lidocaine) - (etoricoxib tizanidine) - (oxycodone hydrochloride naltrexone) ER - AB-001 - abobotulinumtoxin A - ASP-7962 - Atx09-002 - bupivacaine hydrochloride - cebranopadol - Drug for Chronic Low Back Pain - duloxetine hydrochloride DR - eperisone SR - flurbiprofen sodium - MPC-06ID - NKTR-181 - oxycodone hydrochloride ER - PF-06372865 For more information visit http://www.researchandmarkets.com/research/qr..._back_pain
PFE: 35.14 (-0.10), MRK: 58.67 (-0.33), COLL: 18.73 (-0.62), LLY: 85.57 (-2.30), PCRX: 62.89 (-0.55), NKTR: 12.60 (+0.15), PTIE: 1.71 (unch)
Epithelial Ovarian Cancer Pipeline Review 2015 - 49 Companies & 69 Drug Profiles
M2 - Tue Jul 21, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snr9r3/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Adaptimmune Limited - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - Bayer AG - Bionomics Limited - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Celldex Therapeutics, Inc. - Celon Pharma Sp. z o.o. - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Glycotope GmbH - ImmunoGen, Inc. - Immunotope, Inc. - Johnson & Johnson - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NeoStem, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OBI Pharma, Inc. - Oncobiologics, Inc. - Oncolytics Biotech Inc. - Onxeo SA - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Pharma Mar, S.A. For more information visit http://www.researchandmarkets.com/research/snr9r3/epithelial
CLDX: 25.56 (-0.83), NBS: 2.25 (-0.09), CLSN: 2.45 (-0.02), JNJ: 100.34 (-0.03), ABBV: 70.54 (-0.26), EXEL: 6.05 (+0.17), ONCY: 0.66 (+0.02), CERU: 4.26 (-0.07), PFE: 35.14 (-0.10), IMGN: 18.65 (-0.23), AMGN: 163.70 (-0.64), LLY: 85.57 (-2.30), CLVS: 86.16 (+0.10), AZN: 67.64 (-0.21), MRK: 58.67 (-0.33), NVS: 103.71 (-2.41)
Diabetic Neuropathy Therapeutics Pipeline Review 2015 - 16 Companies & 28 Drug Profiles
M2 - Tue Jul 21, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phhqrf/diabetic) has announced the addition of the "Diabetic Neuropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Araim Pharmaceuticals Inc. - Astellas Pharma Inc. - Cebix Incorporated - Eli Lilly and Company - Glucox Biotech AB - Longevity Biotech, Inc - Lpath, Inc. - Neuralstem, Inc. - Omeros Corporation - Pfizer Inc. - R-Tech Ueno, Ltd. - Spinifex Pharmaceuticals Pty Limited - Sumitomo Dainippon Pharma Co., Ltd. - Virobay Inc. - ViroMed Co., Ltd. Drug Profiles - Antimunocel - ARA-290 - ASP-8477 - BBI-21007 - Biologic for Diabetic Nephropathy - BNV-222 - capsaicin - CBX-129801 - Cyndacel-M - Drug for Peripheral Neuropathic Pain and Diabetic Peripheral Neuropathy - EMA-401 - ketoprofen - Lpathomab - Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - NRD-135SE1 - NSI-566 - OMS-721 - Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - PF-05089771 - ranirestat - Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - RTU-1096 - Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Small Molecules for Diabetic Neuropathy - Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Synthetic Peptides for Central Nervous System Disorders and Diabetic Neuropathy - VBY-285 - VM-202 For more information visit http://www.researchandmarkets.com/research/phhqrf/diabetic
PFE: 35.14 (-0.10), LLY: 85.57 (-2.30), VBAY: (), ACOR: 34.46 (-0.83), LPTN: 0.27 (+0.01), OMER: 18.06 (-0.46), CUR: 1.72 (-0.03)
Cytomegalovirus (HHV-5) Infections Therapeutics Pipeline Review 2015 - 29 Companies & 62 Drug Profiles
M2 - Tue Jul 21, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/48mmqt/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - AIMM Therapeutics B.V. - AlphaVax, Inc. - Altor BioScience Corporation - Applied Immune Technologies Ltd - Astellas Pharma Inc. - BioApex, s.r.o. - Bionor Pharma ASA - Biotest AG - CAP-CMV GmbH - Cell Medica Limited - Chimerix, Inc. - GlaxoSmithKline plc - Hookipa Biotech AG - Humabs BioMed SA - INAGEN ApS - iQur Ltd. - Kadmon Corporation, LLC - Lead Discovery Center GmbH - Merck & Co., Inc. - Microbiotix, Inc. - Novartis AG - Pfizer Inc. - Phoenix Biotechnology, Inc. - Spider Biotech - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - VBI Vaccines Inc. - Vical Incorporated For more information visit http://www.researchandmarkets.com/research/48...egalovirus
VICL: 0.64 (-0.03), CMRX: 51.46 (-1.97), PFE: 35.14 (-0.10), MRK: 58.67 (-0.33), VBIV: 2.48 (-0.04), GSK: 42.63 (-0.39), NVS: 103.71 (-2.41)
3 High-Dividend Pharmaceutical Stocks to Buy
at The Street - Tue Jul 21, 7:48AM CDT
With Eli Lilly & Co. experimenting with a new drug for Alzheimer's disease, we decided to check Quant Ratings for pharmaceutical stocks to buy.
JNJ: 100.34 (-0.03), PFE: 35.14 (-0.10), LLY: 85.57 (-2.30), NVS: 103.71 (-2.41)
America's Most-Preferred Bone Health Brand Launches New Caltrate(R) Bone & Joint Health Supplement
Business Wire - Tue Jul 21, 7:00AM CDT
Pfizer Consumer Healthcare, the makers of America's most-preferred bone health supplement brand, Caltrate(R), today announced the launch of Caltrate(R) Bone & Joint Health, a new, once-daily supplement. Caltrate(R) Bone & Joint Health is a 3-in-1, triple action product that delivers:
PFE: 35.14 (-0.10)
Soft Tissue Sarcoma Therapeutics Pipeline Report 2015 - Review of 46 Companies & 64 Drug Profiles
M2 - Tue Jul 21, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vws7wm/soft_tissue) has announced the addition of the "Soft Tissue Sarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - Altor BioScience Corporation - Amgen Inc. - Bayer AG - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - CASI Pharmaceuticals Inc. - Celgene Corporation - Cellectar Biosciences, Inc. - CytRx Corporation - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Exelixis, Inc. - Gem Pharmaceuticals, LLC - Immune Design Corp. - Karyopharm Therapeutics, Inc. - Loxo Oncology, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Mirati Therapeutics Inc. - MolMed S.p.A. - Morphotek, Inc. - Nanobiotix - Neotropix, Inc. - Novartis AG - Oncos Therapeutics Ltd. - Onxeo SA - Pfizer Inc. - Pharma Mar, S.A. - Plexxikon Inc. For more information visit http://www.researchandmarkets.com/research/vw...oft_tissue
LOXO: 17.44 (-0.35), CLRB: 3.55 (unch), IMDZ: 26.06 (-0.09), PFE: 35.14 (-0.10), AMGN: 163.70 (-0.64), LLY: 85.57 (-2.30), EPZM: 22.18 (+0.05), CASI: 1.66 (-0.02), MACK: 9.84 (-0.41), BLCM: 19.46 (-0.50), MRK: 58.67 (-0.33), CYTR: 3.04 (-0.76), MRTX: 31.46 (-1.51), NVS: 103.71 (-2.41), KPTI: 23.26 (-0.72), EXEL: 6.05 (+0.17), CELGZ: 2.19 (+0.01)
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Pipeline Review 2015 - Analysis of 35 Companies & 43 Drug Profiles
M2 - Tue Jul 21, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6dp6kl/bile_duct_cancer) has announced the addition of the "Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - Agios Pharmaceuticals, Inc. - Ariad Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca PLC - Bayer AG - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - CellAct Pharma GmbH - Concordia Healthcare Corp. - Cornerstone Pharmaceuticals, Inc. - Delcath Systems, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Komipharm International Co., Ltd. - Mebiopharm Co., Ltd. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - NuCana BioMed Limited - OncoTherapy Science, Inc. - Panacea Pharmaceuticals, Inc. - PCI Biotech AS - Pfizer Inc. - Provecs Medical GmbH - Sanofi - Senhwa Biosciences, Inc. - Spectrum Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - VasGene Therapeutics, Inc. Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - AG-120 - ARN-5032 - ARQ-087 - BBI-503 - BGJ-398 - binimetinib - cabozantinib s-malate - CAP-7.1 - CC-90007 - CPI-613 - dasatinib - DKN-01 - elpamotide - evofosfamide - gemcitabine hydrochloride - Im-01 - KML-001 - MBPY-005 - melphalan - merestinib - MK-2206 - NUC-1031 - OCVC-01 - paclitaxel albumin bound - PAN-622 - pembrolizumab - ponatinib hydrochloride - porfimer sodium For more information visit http://www.researchandmarkets.com/research/6d...uct_cancer
PFE: 35.14 (-0.10), ARQL: 1.84 (+0.01), SPPI: 7.27 (-0.14), LLY: 85.57 (-2.30), GSK: 42.63 (-0.39), BMY: 68.87 (-1.10), MACK: 9.84 (-0.41), MRK: 58.67 (-0.33), AZN: 67.64 (-0.21), AGIO: 114.09 (-1.02), DCTH: 0.49 (-0.03), NVS: 103.71 (-2.41), ARRY: 6.73 (-0.06), CELGZ: 2.19 (+0.01), CXRX: 80.55 (+1.70), EXEL: 6.05 (+0.17)
Acute Coronary Syndrome Therapeutics Pipeline Report 2015 - 15 Companies & 23 Drug Profiles
M2 - Tue Jul 21, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qf9st8/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - advanceCor GmbH - Arena Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Athera Biotechnologies AB - Auspex Pharmaceuticals, Inc. - Bayer AG - Esperion Therapeutics, Inc. - GlaxoSmithKline Plc - Lee's Pharmaceutical Holdings Limited - MedImmune, LLC - Pfizer Inc. - The Medicines Company - Vitae Pharmaceuticals, Inc. - XOMA Corporation Drug Profiles - 4-WF - AEM-28 - AEM-28-02 - Artpep-2 - Biologics for Acute Coronary Syndrome - bivalirudin - cangrelor - COR-2 - COR-3 - gevokizumab - losmapimod - MDCO-216 - MEDI-6012 - MTP-131 - PC-mAb - PF-06282999 - PMC-6 - PR-15 - rivaroxaban - SD-970 - temanogrel hydrochloride - VTP-38443 - ZK-001 For more information visit http://www.researchandmarkets.com/research/qf...e_coronary
ESPR: 95.87 (-0.90), PFE: 35.14 (-0.10), AZN: 67.64 (-0.21), VTAE: 10.77 (-0.05), ASPX: 100.96 (unch), GSK: 42.63 (-0.39), ARNA: 4.30 (-0.05), XOMA: 4.39 (-0.13)
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Pipeline Review, H1 2015 - 39 Companies & 45 Drug Profiles
M2 - Tue Jul 21, 4:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7tfffq/plaque_psoriasis) has announced the addition of the "Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Almirall, S.A. - Amgen Inc. - Avesthagen Limited - Avexxin AS - Biocon Limited - Biotie Therapies Corp. - Can-Fite BioPharma Ltd. - Celltrion, Inc. - Circassia Pharmaceuticals plc - Coherus BioSciences, Inc. - Creabilis SA - Delenex Therapeutics AG - Dermira Inc. - Epirus Biopharmaceuticals, Inc. - Forward Pharma A/S - Galectin Therapeutics, Inc. - Genor BioPharma Co., Ltd. - Idera Pharmaceuticals, Inc. - Invion Limited - Johnson & Johnson - Kadmon Corporation, LLC - Kineta, Inc. - Kyowa Hakko Kirin Co., Ltd. - LEO Pharma A/S - Lipidor AB - Mabion SA - Maruho Co., Ltd. - Momenta Pharmaceuticals, Inc. - Oncobiologics, Inc. - Pfizer Inc. - Promius Pharma, LLC - Protalix BioTherapeutics, Inc. - Provectus Biopharmaceuticals, Inc. - R-Tech Ueno, Ltd. - TetraLogic Pharmaceuticals Drug Profiles - (betamethasone dipropionate bexarotene) - (calcipotriene betamethasone dipropionate) - (calcipotriene betamethasone) - adalimumab biosimilar - AM-001 - ASKP-1240 - AVX-001 - betamethasone maxacalcitol - bimekizumab - brodalumab - BTT-1023 - calcipotriene - CF-101 - CIR-001 - CT-327 - dalazatide - DFD-01 - DFD-06 - dimethyl fumarate - DLX-105 - DRM-02 - etanercept biosimilar - GK-664S - GR-MD-02 - guselkumab - IDP-118 - IMO-8400 - infliximab biosimilar - INV-103 - KD-025 - LEO-32731 - LP-0113 - M-801801 - MOL-4239 - MOL-4249 For more information visit http://www.researchandmarkets.com/research/7t..._psoriasis
PFE: 35.14 (-0.10), GALT: 2.67 (+0.03), AMGN: 163.70 (-0.64), MNTA: 22.89 (-0.25), CHRS: 37.08 (-0.10), PVCT: 0.46 (unch), CANF: 1.92 (unch), JNJ: 100.34 (-0.03), IDRA: 3.63 (+0.14), DERM: 23.05 (+0.47), FWP: 37.75 (-0.53)
Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H1 2015 - 23 Companies & 29 Drug Profiles
M2 - Tue Jul 21, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hs6grh/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ascendis Pharma A/S - AstraZeneca PLC - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Delpor, Inc. - Eli Lilly and Company - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - MarcoPolo Pharmaceuticals SA - Navigen Pharmaceuticals, Inc. - Neurocrine Biosciences, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - SK Biopharmaceuticals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - Zogenix, Inc. - Zysis Limited Drug Profiles - ACP-005 - aripiprazole - aripiprazole CR - BRDK-98958073 - cariprazine - CNV-1061436 - DP-VPA - Drug for Bipolar Disorder - Drug for Cancer and Neurodegenerative Disease - Endoxifen - ITI-007 - KP-303 - lurasidone hydrochloride - LY-2979165 - NP-202 - paliperidone palmitate - PGW-5 - quetiapine fumarate ER - ramelteon - risperidone - RP-5063 - SKL-PSY - Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia - Small Molecule to Inhibit VMAT-2 for Schizophrenia, Bipolar Disorder and Movement Disorders - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Synthetic Peptides to Inhibit IMPase for Bipolar Disorder - uridine triacetate - ziprasidone hydrochloride For more information visit http://www.researchandmarkets.com/research/hs...r_disorder
NBIX: 51.89 (-0.57), KMPH: 18.10 (+0.17), ASND: 21.00 (-0.43), ZGNX: 20.72 (+0.34), PFE: 35.14 (-0.10), AZN: 67.64 (-0.21), TEVA: 63.35 (-0.26), ITCI: 28.95 (-1.15), LLY: 85.57 (-2.30), OMER: 18.06 (-0.46)
Pfizer (PFE) Approaches New Upside Target of $35.19
Comtex SmarTrend(R) - Mon Jul 20, 9:06AM CDT
Pfizer (NYSE
FE) has opened bullishly above the pivot of $35.02 today and has reached the first level of resistance at $35.13. Analysts will be watching for a cross of the next upside pivot targets of $35.19 and $35.36.
PFE: 35.14 (-0.10)
Pfizer is expanding its vaccine portfolio, developing others
By The Associated Press - AP - Tue Jul 21, 5:08PM CDT
Pfizer has expanded its research on vaccines to eventually safeguard people from cradle to grave, from shots for pregnant women to protect their babies from the moment of birth to vaccines for senior citizens with waning immune systems, company officials said Tuesday during a media briefing.
BAX: 37.85 (+0.19), PFE: 35.14 (-0.10)
Business Highlights
By The Associated Press - AP - Tue Jul 21, 5:00PM CDT
___
JPM: 69.10 (-0.16), PFE: 35.14 (-0.10), C: 59.10 (+0.25), AMGN: 163.70 (-0.64), BAC: 18.08 (-0.04)
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 1:52PM CDT
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
AGN: 317.00 (-0.75), JNJ: 100.34 (-0.03), ACHN: 9.26 (-0.10), PFE: 35.14 (-0.10), ABBV: 70.54 (-0.26), JUNO: 50.10 (-0.03), LLY: 85.57 (-2.30), SNY: 52.99 (-0.26)
Pharma Stock Outlook - July 2015 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 1:52PM CDT
Pharma Stock Outlook - July 2015 - Industry Outlook
AGN: 317.00 (-0.75), JNJ: 100.34 (-0.03), ACHN: 9.26 (-0.10), PFE: 35.14 (-0.10), ABBV: 70.54 (-0.26), JUNO: 50.10 (-0.03), LLY: 85.57 (-2.30), SNY: 52.99 (-0.26)
Europe approves Amgen's first-in-class cholesterol drug
By MATTHEW PERRONE - AP - Tue Jul 21, 1:32PM CDT
WASHINGTON (AP) — Amgen on Tuesday received European approval for its first-of-a-kind cholesterol drug that lowers levels of the artery-clogging substance more than older drugs that have been prescribed for decades.
PFE: 35.14 (-0.10), AMGN: 163.70 (-0.64)
Global Fibrosis Therapeutics Pipeline Report 2015 - 32 Companies & 51 Drug Profiles
M2 - Tue Jul 21, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjw3lt/fibrosis) has announced the addition of the "Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - AiCuris GmbH & Co. KG - AnaMar AB - Arena Pharmaceuticals, Inc. - Bristol-Myers Squibb Company - Digna Biotech, S.L. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Five Prime Therapeutics, Inc. - Galectin Therapeutics, Inc. - GenKyoTex S.A. - GlycoMimetics, Inc. - HanAll Biopharma Co., Ltd. - Intercept Pharmaceuticals, Inc. - Isarna Therapeutics GmbH - KineMed, Inc. - Lycera Corp. - MandalMed, Inc. - miRagen Therapeutics, Inc. - Neumedicines Inc. - Pfizer Inc. - Promedior, Inc. - ProMetic Life Sciences Inc. - RuiYi Inc. - Scholar Rock, Inc. - Siena Biotech S.p.A. - SK Chemicals Co., Ltd. - Taisho Pharmaceutical Co., Ltd. - TRACON Pharmaceuticals, Inc. - UCB S.A. - Vericel Corporation - VivaCell Biotechnology Espana S.L. For more information visit http://www.researchandmarkets.com/research/rjw3lt/fibrosis
VCEL: 3.47 (-0.08), KNMD: (), PFE: 35.14 (-0.10), GALT: 2.67 (+0.03), GLYC: 7.52 (+0.10), BMY: 68.87 (-1.10), ICPT: 271.32 (-5.83), FGEN: 24.67 (-0.07), TCON: 13.13 (unch), ARNA: 4.30 (-0.05), XLRN: 30.79 (-1.79), FPRX: 24.89 (-0.29)
Sickle Cell Disease Pipeline Review, H1 2015 - 27 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rrc4sf/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Alnylam Pharmaceuticals, Inc. - Bluebird bio, Inc. - Bristol-Myers Squibb Company - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Erytech Pharma SA - Gamida Cell Ltd. - Gilead Sciences, Inc. - Global Blood Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Johnson & Johnson - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - Pfizer Inc. - PharmaEssentia Corporation - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sangamo BioSciences, Inc. - Sanofi - SynZyme Technologies, LLC For more information visit http://www.researchandmarkets.com/research/rr...ickle_cell
JNJ: 100.34 (-0.03), ISIS: 56.18 (+0.50), GILD: 117.78 (-0.42), PFE: 35.14 (-0.10), SGMO: 9.71 (-0.25), BMY: 68.87 (-1.10), NVS: 103.71 (-2.41), XLRN: 30.79 (-1.79)
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Pipeline Report 2015 - 37 Companies & 57 Drug Profiles
M2 - Tue Jul 21, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vgmkjs/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Absynth Biologics Limited - Actelion Ltd - ActogeniX NV - Adenium Biotech ApS - AIMM Therapeutics B.V. - Akthelia pharmaceuticals ehf - AmpliPhi Biosciences Corporation - Assembly Biosciences, Inc. - AvidBiotics Corp. - C3 Jian, Inc - Daiichi Sankyo Company, Limited - Evec, Inc. - GangaGen Inc. - ImmunoBiology Ltd. - Immuron Limited - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Merck & Co., Inc. - MGB Biopharma Limited - Microbiotix, Inc. - Micropharm Ltd - Nanotherapeutics, Inc. - Novabiotics Ltd - Oragenics, Inc. - Pfizer Inc. - Procarta Biosystems Ltd - Prokarium Ltd. - Sanofi Pasteur SA - Sarum Biosciences Limited - Sequella, Inc. - Shire Plc - Sorrento Therapeutics, Inc. - Stellar Biotechnologies, Inc. - Summit Therapeutics plc. - Synthetic Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/vg...lostridium
PFE: 35.14 (-0.10), SRNE: 23.98 (-0.01), INO: 7.31 (-0.19), SYN: 3.41 (+0.24), MRK: 58.67 (-0.33), SHPG: 255.23 (-2.57), ASMB: 16.99 (-0.46), OGEN: 1.74 (+0.04)
Low Back Pain Therapeutics Pipeline Review 2015 - 17 Companies & 19 Drug Profiles
M2 - Tue Jul 21, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qrggl2/low_back_pain) has announced the addition of the "Low Back Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aestus Therapeutics, Inc. - Astellas Pharma Inc. - Collegium Pharmaceutical, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Frontier Biotechnologies Co., Ltd - Grunenthal GmbH - Ipsen S.A. - MEDRx Co., Ltd. - Merck & Co., Inc. - Mesoblast Limited - Nektar Therapeutics - Pacira Pharmaceuticals, Inc. - Paladin Labs Inc. - Pfizer Inc. - Stayble Therapeutics - Teikoku Pharma USA, Inc. Drug Profiles - (acetaminophen tramadol hydrochloride) - (diclofenac sodium eperisone) - (etodolac lidocaine) - (etoricoxib tizanidine) - (oxycodone hydrochloride naltrexone) ER - AB-001 - abobotulinumtoxin A - ASP-7962 - Atx09-002 - bupivacaine hydrochloride - cebranopadol - Drug for Chronic Low Back Pain - duloxetine hydrochloride DR - eperisone SR - flurbiprofen sodium - MPC-06ID - NKTR-181 - oxycodone hydrochloride ER - PF-06372865 For more information visit http://www.researchandmarkets.com/research/qr..._back_pain
PFE: 35.14 (-0.10), MRK: 58.67 (-0.33), COLL: 18.73 (-0.62), LLY: 85.57 (-2.30), PCRX: 62.89 (-0.55), NKTR: 12.60 (+0.15), PTIE: 1.71 (unch)
Epithelial Ovarian Cancer Pipeline Review 2015 - 49 Companies & 69 Drug Profiles
M2 - Tue Jul 21, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snr9r3/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Adaptimmune Limited - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - Bayer AG - Bionomics Limited - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Celldex Therapeutics, Inc. - Celon Pharma Sp. z o.o. - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Glycotope GmbH - ImmunoGen, Inc. - Immunotope, Inc. - Johnson & Johnson - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NeoStem, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OBI Pharma, Inc. - Oncobiologics, Inc. - Oncolytics Biotech Inc. - Onxeo SA - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Pharma Mar, S.A. For more information visit http://www.researchandmarkets.com/research/snr9r3/epithelial
CLDX: 25.56 (-0.83), NBS: 2.25 (-0.09), CLSN: 2.45 (-0.02), JNJ: 100.34 (-0.03), ABBV: 70.54 (-0.26), EXEL: 6.05 (+0.17), ONCY: 0.66 (+0.02), CERU: 4.26 (-0.07), PFE: 35.14 (-0.10), IMGN: 18.65 (-0.23), AMGN: 163.70 (-0.64), LLY: 85.57 (-2.30), CLVS: 86.16 (+0.10), AZN: 67.64 (-0.21), MRK: 58.67 (-0.33), NVS: 103.71 (-2.41)
Diabetic Neuropathy Therapeutics Pipeline Review 2015 - 16 Companies & 28 Drug Profiles
M2 - Tue Jul 21, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phhqrf/diabetic) has announced the addition of the "Diabetic Neuropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Araim Pharmaceuticals Inc. - Astellas Pharma Inc. - Cebix Incorporated - Eli Lilly and Company - Glucox Biotech AB - Longevity Biotech, Inc - Lpath, Inc. - Neuralstem, Inc. - Omeros Corporation - Pfizer Inc. - R-Tech Ueno, Ltd. - Spinifex Pharmaceuticals Pty Limited - Sumitomo Dainippon Pharma Co., Ltd. - Virobay Inc. - ViroMed Co., Ltd. Drug Profiles - Antimunocel - ARA-290 - ASP-8477 - BBI-21007 - Biologic for Diabetic Nephropathy - BNV-222 - capsaicin - CBX-129801 - Cyndacel-M - Drug for Peripheral Neuropathic Pain and Diabetic Peripheral Neuropathy - EMA-401 - ketoprofen - Lpathomab - Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - NRD-135SE1 - NSI-566 - OMS-721 - Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - PF-05089771 - ranirestat - Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - RTU-1096 - Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Small Molecules for Diabetic Neuropathy - Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Synthetic Peptides for Central Nervous System Disorders and Diabetic Neuropathy - VBY-285 - VM-202 For more information visit http://www.researchandmarkets.com/research/phhqrf/diabetic
PFE: 35.14 (-0.10), LLY: 85.57 (-2.30), VBAY: (), ACOR: 34.46 (-0.83), LPTN: 0.27 (+0.01), OMER: 18.06 (-0.46), CUR: 1.72 (-0.03)
Cytomegalovirus (HHV-5) Infections Therapeutics Pipeline Review 2015 - 29 Companies & 62 Drug Profiles
M2 - Tue Jul 21, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/48mmqt/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - AIMM Therapeutics B.V. - AlphaVax, Inc. - Altor BioScience Corporation - Applied Immune Technologies Ltd - Astellas Pharma Inc. - BioApex, s.r.o. - Bionor Pharma ASA - Biotest AG - CAP-CMV GmbH - Cell Medica Limited - Chimerix, Inc. - GlaxoSmithKline plc - Hookipa Biotech AG - Humabs BioMed SA - INAGEN ApS - iQur Ltd. - Kadmon Corporation, LLC - Lead Discovery Center GmbH - Merck & Co., Inc. - Microbiotix, Inc. - Novartis AG - Pfizer Inc. - Phoenix Biotechnology, Inc. - Spider Biotech - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - VBI Vaccines Inc. - Vical Incorporated For more information visit http://www.researchandmarkets.com/research/48...egalovirus
VICL: 0.64 (-0.03), CMRX: 51.46 (-1.97), PFE: 35.14 (-0.10), MRK: 58.67 (-0.33), VBIV: 2.48 (-0.04), GSK: 42.63 (-0.39), NVS: 103.71 (-2.41)
3 High-Dividend Pharmaceutical Stocks to Buy
at The Street - Tue Jul 21, 7:48AM CDT
With Eli Lilly & Co. experimenting with a new drug for Alzheimer's disease, we decided to check Quant Ratings for pharmaceutical stocks to buy.
JNJ: 100.34 (-0.03), PFE: 35.14 (-0.10), LLY: 85.57 (-2.30), NVS: 103.71 (-2.41)
America's Most-Preferred Bone Health Brand Launches New Caltrate(R) Bone & Joint Health Supplement
Business Wire - Tue Jul 21, 7:00AM CDT
Pfizer Consumer Healthcare, the makers of America's most-preferred bone health supplement brand, Caltrate(R), today announced the launch of Caltrate(R) Bone & Joint Health, a new, once-daily supplement. Caltrate(R) Bone & Joint Health is a 3-in-1, triple action product that delivers:
PFE: 35.14 (-0.10)
Soft Tissue Sarcoma Therapeutics Pipeline Report 2015 - Review of 46 Companies & 64 Drug Profiles
M2 - Tue Jul 21, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vws7wm/soft_tissue) has announced the addition of the "Soft Tissue Sarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - Altor BioScience Corporation - Amgen Inc. - Bayer AG - Bellicum Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - CASI Pharmaceuticals Inc. - Celgene Corporation - Cellectar Biosciences, Inc. - CytRx Corporation - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Eli Lilly and Company - EpiZyme, Inc. - Exelixis, Inc. - Gem Pharmaceuticals, LLC - Immune Design Corp. - Karyopharm Therapeutics, Inc. - Loxo Oncology, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Mirati Therapeutics Inc. - MolMed S.p.A. - Morphotek, Inc. - Nanobiotix - Neotropix, Inc. - Novartis AG - Oncos Therapeutics Ltd. - Onxeo SA - Pfizer Inc. - Pharma Mar, S.A. - Plexxikon Inc. For more information visit http://www.researchandmarkets.com/research/vw...oft_tissue
LOXO: 17.44 (-0.35), CLRB: 3.55 (unch), IMDZ: 26.06 (-0.09), PFE: 35.14 (-0.10), AMGN: 163.70 (-0.64), LLY: 85.57 (-2.30), EPZM: 22.18 (+0.05), CASI: 1.66 (-0.02), MACK: 9.84 (-0.41), BLCM: 19.46 (-0.50), MRK: 58.67 (-0.33), CYTR: 3.04 (-0.76), MRTX: 31.46 (-1.51), NVS: 103.71 (-2.41), KPTI: 23.26 (-0.72), EXEL: 6.05 (+0.17), CELGZ: 2.19 (+0.01)
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Pipeline Review 2015 - Analysis of 35 Companies & 43 Drug Profiles
M2 - Tue Jul 21, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6dp6kl/bile_duct_cancer) has announced the addition of the "Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - Agios Pharmaceuticals, Inc. - Ariad Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca PLC - Bayer AG - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - CellAct Pharma GmbH - Concordia Healthcare Corp. - Cornerstone Pharmaceuticals, Inc. - Delcath Systems, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Komipharm International Co., Ltd. - Mebiopharm Co., Ltd. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - NuCana BioMed Limited - OncoTherapy Science, Inc. - Panacea Pharmaceuticals, Inc. - PCI Biotech AS - Pfizer Inc. - Provecs Medical GmbH - Sanofi - Senhwa Biosciences, Inc. - Spectrum Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - VasGene Therapeutics, Inc. Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - AG-120 - ARN-5032 - ARQ-087 - BBI-503 - BGJ-398 - binimetinib - cabozantinib s-malate - CAP-7.1 - CC-90007 - CPI-613 - dasatinib - DKN-01 - elpamotide - evofosfamide - gemcitabine hydrochloride - Im-01 - KML-001 - MBPY-005 - melphalan - merestinib - MK-2206 - NUC-1031 - OCVC-01 - paclitaxel albumin bound - PAN-622 - pembrolizumab - ponatinib hydrochloride - porfimer sodium For more information visit http://www.researchandmarkets.com/research/6d...uct_cancer
PFE: 35.14 (-0.10), ARQL: 1.84 (+0.01), SPPI: 7.27 (-0.14), LLY: 85.57 (-2.30), GSK: 42.63 (-0.39), BMY: 68.87 (-1.10), MACK: 9.84 (-0.41), MRK: 58.67 (-0.33), AZN: 67.64 (-0.21), AGIO: 114.09 (-1.02), DCTH: 0.49 (-0.03), NVS: 103.71 (-2.41), ARRY: 6.73 (-0.06), CELGZ: 2.19 (+0.01), CXRX: 80.55 (+1.70), EXEL: 6.05 (+0.17)
Acute Coronary Syndrome Therapeutics Pipeline Report 2015 - 15 Companies & 23 Drug Profiles
M2 - Tue Jul 21, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qf9st8/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - advanceCor GmbH - Arena Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Athera Biotechnologies AB - Auspex Pharmaceuticals, Inc. - Bayer AG - Esperion Therapeutics, Inc. - GlaxoSmithKline Plc - Lee's Pharmaceutical Holdings Limited - MedImmune, LLC - Pfizer Inc. - The Medicines Company - Vitae Pharmaceuticals, Inc. - XOMA Corporation Drug Profiles - 4-WF - AEM-28 - AEM-28-02 - Artpep-2 - Biologics for Acute Coronary Syndrome - bivalirudin - cangrelor - COR-2 - COR-3 - gevokizumab - losmapimod - MDCO-216 - MEDI-6012 - MTP-131 - PC-mAb - PF-06282999 - PMC-6 - PR-15 - rivaroxaban - SD-970 - temanogrel hydrochloride - VTP-38443 - ZK-001 For more information visit http://www.researchandmarkets.com/research/qf...e_coronary
ESPR: 95.87 (-0.90), PFE: 35.14 (-0.10), AZN: 67.64 (-0.21), VTAE: 10.77 (-0.05), ASPX: 100.96 (unch), GSK: 42.63 (-0.39), ARNA: 4.30 (-0.05), XOMA: 4.39 (-0.13)
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Pipeline Review, H1 2015 - 39 Companies & 45 Drug Profiles
M2 - Tue Jul 21, 4:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7tfffq/plaque_psoriasis) has announced the addition of the "Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Almirall, S.A. - Amgen Inc. - Avesthagen Limited - Avexxin AS - Biocon Limited - Biotie Therapies Corp. - Can-Fite BioPharma Ltd. - Celltrion, Inc. - Circassia Pharmaceuticals plc - Coherus BioSciences, Inc. - Creabilis SA - Delenex Therapeutics AG - Dermira Inc. - Epirus Biopharmaceuticals, Inc. - Forward Pharma A/S - Galectin Therapeutics, Inc. - Genor BioPharma Co., Ltd. - Idera Pharmaceuticals, Inc. - Invion Limited - Johnson & Johnson - Kadmon Corporation, LLC - Kineta, Inc. - Kyowa Hakko Kirin Co., Ltd. - LEO Pharma A/S - Lipidor AB - Mabion SA - Maruho Co., Ltd. - Momenta Pharmaceuticals, Inc. - Oncobiologics, Inc. - Pfizer Inc. - Promius Pharma, LLC - Protalix BioTherapeutics, Inc. - Provectus Biopharmaceuticals, Inc. - R-Tech Ueno, Ltd. - TetraLogic Pharmaceuticals Drug Profiles - (betamethasone dipropionate bexarotene) - (calcipotriene betamethasone dipropionate) - (calcipotriene betamethasone) - adalimumab biosimilar - AM-001 - ASKP-1240 - AVX-001 - betamethasone maxacalcitol - bimekizumab - brodalumab - BTT-1023 - calcipotriene - CF-101 - CIR-001 - CT-327 - dalazatide - DFD-01 - DFD-06 - dimethyl fumarate - DLX-105 - DRM-02 - etanercept biosimilar - GK-664S - GR-MD-02 - guselkumab - IDP-118 - IMO-8400 - infliximab biosimilar - INV-103 - KD-025 - LEO-32731 - LP-0113 - M-801801 - MOL-4239 - MOL-4249 For more information visit http://www.researchandmarkets.com/research/7t..._psoriasis
PFE: 35.14 (-0.10), GALT: 2.67 (+0.03), AMGN: 163.70 (-0.64), MNTA: 22.89 (-0.25), CHRS: 37.08 (-0.10), PVCT: 0.46 (unch), CANF: 1.92 (unch), JNJ: 100.34 (-0.03), IDRA: 3.63 (+0.14), DERM: 23.05 (+0.47), FWP: 37.75 (-0.53)
Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H1 2015 - 23 Companies & 29 Drug Profiles
M2 - Tue Jul 21, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hs6grh/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ascendis Pharma A/S - AstraZeneca PLC - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Delpor, Inc. - Eli Lilly and Company - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - MarcoPolo Pharmaceuticals SA - Navigen Pharmaceuticals, Inc. - Neurocrine Biosciences, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Reviva Pharmaceuticals Inc. - Richter Gedeon Nyrt. - SK Biopharmaceuticals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - Zogenix, Inc. - Zysis Limited Drug Profiles - ACP-005 - aripiprazole - aripiprazole CR - BRDK-98958073 - cariprazine - CNV-1061436 - DP-VPA - Drug for Bipolar Disorder - Drug for Cancer and Neurodegenerative Disease - Endoxifen - ITI-007 - KP-303 - lurasidone hydrochloride - LY-2979165 - NP-202 - paliperidone palmitate - PGW-5 - quetiapine fumarate ER - ramelteon - risperidone - RP-5063 - SKL-PSY - Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia - Small Molecule to Inhibit VMAT-2 for Schizophrenia, Bipolar Disorder and Movement Disorders - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Synthetic Peptides to Inhibit IMPase for Bipolar Disorder - uridine triacetate - ziprasidone hydrochloride For more information visit http://www.researchandmarkets.com/research/hs...r_disorder
NBIX: 51.89 (-0.57), KMPH: 18.10 (+0.17), ASND: 21.00 (-0.43), ZGNX: 20.72 (+0.34), PFE: 35.14 (-0.10), AZN: 67.64 (-0.21), TEVA: 63.35 (-0.26), ITCI: 28.95 (-1.15), LLY: 85.57 (-2.30), OMER: 18.06 (-0.46)
Pfizer (PFE) Approaches New Upside Target of $35.19
Comtex SmarTrend(R) - Mon Jul 20, 9:06AM CDT
Pfizer (NYSE
FE) has opened bullishly above the pivot of $35.02 today and has reached the first level of resistance at $35.13. Analysts will be watching for a cross of the next upside pivot targets of $35.19 and $35.36. PFE: 35.14 (-0.10)
